Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

402 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, Cortes J, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D. Schettini F, et al. Among authors: wildiers h. Cancer Treat Rev. 2022 Dec;111:102468. doi: 10.1016/j.ctrv.2022.102468. Epub 2022 Sep 28. Cancer Treat Rev. 2022. PMID: 36202026 Free article. Review.
Taxanes in elderly breast cancer patients.
Wildiers H, Paridaens R. Wildiers H, et al. Cancer Treat Rev. 2004 Jun;30(4):333-42. doi: 10.1016/j.ctrv.2003.12.001. Cancer Treat Rev. 2004. PMID: 15145508 Review.
A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients.
Wildiers H, Jurcut R, Ganame J, Herbots L, Neven P, De Backer J, Denys H, Cocquyt V, Rademakers F, Voigt JU, Paridaens R. Wildiers H, et al. Crit Rev Oncol Hematol. 2008 Aug;67(2):133-8. doi: 10.1016/j.critrevonc.2008.01.001. Epub 2008 Mar 4. Crit Rev Oncol Hematol. 2008. PMID: 18308582
Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.
Wildiers H, Fontaine C, Vuylsteke P, Martens M, Canon JL, Wynendaele W, Focan C, De Greve J, Squifflet P, Paridaens R. Wildiers H, et al. Breast Cancer Res Treat. 2010 Sep;123(2):463-9. doi: 10.1007/s10549-010-1066-x. Epub 2010 Jul 22. Breast Cancer Res Treat. 2010. PMID: 20652398 Clinical Trial.
Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers.
van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ. van Schooneveld E, et al. Among authors: wildiers h. Breast Cancer Res. 2012 Feb 21;14(1):R34. doi: 10.1186/bcr3127. Breast Cancer Res. 2012. PMID: 22353773 Free PMC article.
Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.
Vulsteke C, Pfeil AM, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Peeters M, van Dam P, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H. Vulsteke C, et al. Among authors: wildiers h. Breast Cancer Res Treat. 2014 Oct;147(3):557-70. doi: 10.1007/s10549-014-3105-5. Epub 2014 Aug 29. Breast Cancer Res Treat. 2014. PMID: 25168315 Clinical Trial.
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.
Diéras V, Wildiers H, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, Gonçalves A, Romieu G, Limentani SA, Jerusalem G, Lakshmaiah KC, Roché H, Sánchez-Rovira P, Pienkowski T, Seguí Palmer MÁ, Li A, Sun YN, Pickett CA, Slamon DJ. Diéras V, et al. Among authors: wildiers h. Breast. 2015 Jun;24(3):182-90. doi: 10.1016/j.breast.2014.11.003. Epub 2015 Mar 5. Breast. 2015. PMID: 25747197 Clinical Trial.
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.
Lambertini M, Pinto AC, Ameye L, Jongen L, Del Mastro L, Puglisi F, Poggio F, Bonotto M, Floris G, Van Asten K, Wildiers H, Neven P, de Azambuja E, Paesmans M, Azim HA Jr. Lambertini M, et al. Among authors: wildiers h. Br J Cancer. 2016 Dec 6;115(12):1471-1478. doi: 10.1038/bjc.2016.359. Epub 2016 Nov 1. Br J Cancer. 2016. PMID: 27802449 Free PMC article.
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.
Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J. Dickler MN, et al. Among authors: wildiers h. Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22. Clin Cancer Res. 2017. PMID: 28533223 Free PMC article. Clinical Trial.
402 results